Tag: chemotherapy-induced nausea and vomiting cinv market

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Changed, over the years?

There has been a significant increase in the market size of chemotherapy-induced nausea and vomiting (CINV) in the past years. Anticipated growth from $2.92 billion in 2024 to $3.15 billion in 2025, translating to a compound annual growth rate (CAGR) of 7.9%, is predicted. Factors such as the escalating use of chemotherapy, enhanced antiemetic agents, developed clinical guidelines, and patient advocacy are credited for the growth witnessed in the historical period.

How Much Will the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Be Worth in 2029?

The market size for chemotherapy-induced nausea and vomiting (CINV) is anticipated to witness significant growth in the upcoming years. The CINV market size is projected to reach $4.2 billion in 2029, with a compound annual growth rate (CAGR) of 7.5%. This projected growth in the forecast period is due to factors such as personalized medicine, the progress in antiemetic agents, telehealth and remote monitoring, and health equity initiatives. Key trends expected during the forecast period encompass combined antiemetic therapies, supportive care services, digital health instruments, and survivorship care.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

Which is the Largest Company in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

What Are the Main Market Drivers in the Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?

As cancer rates continue to rise, it is anticipated that the chemotherapy-induced nausea and vomiting (CINV) market will likewise experience growth. Cancer occurs when cells develop without restraint and spread throughout the body. The rising occurrence of cancer has prompted a stronger drive towards devising more potent and specific anti-emetic therapies to manage CINV, a bothersome by-product of chemotherapy treatment. The intensified attention towards managing CINV has contributed to progress in comprehending its causative biological processes and crafting new treatments. The American Cancer Society, a volunteer health group devoted to eliminating cancer in the U.S, reported that by January 2023, there would approximately be 1.9 million new cancer cases and 609,820 cancer-related deaths. Consequently, the mounting prevalence of cancer is expected to stimulate the chemotherapy-induced nausea and vomiting (CINV) market.

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Driver: Regulatory Initiatives Contribute to Market Growth

 

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

How Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segments Structured?

The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented –

1) By Form: Injectables, Oral, Transdermal Patches

2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class

3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

Subsegments:

1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

2) By Oral: Tablets, Capsules, Liquid Formulations

3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

What Strategic Trends Are Transforming the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

In the chemotherapy-induced nausea and vomiting (CINV) industry, key players are adopting strategies such as launching new products with advanced features like fixed intravenous antiemetic to hold a competitive edge. This term signifies a medication that is given through an IV at a prespecified dose to alleviate or prevent nausea and vomiting, a common occurrence post surgery or during chemotherapy. For instance, Glenmark Pharmaceuticals Limited, a producer of pharmaceuticals, generic drugs, and consumer health products based in India, rolled out AKYNZEO I.V. in India in January 2023, marking the first appearance of a fixed intravenous antiemetic combo produced for CINV prevention. The product blends netupitant and palonosetron, offering a treatment for both immediate and delayed instances of nausea and vomiting. It offers the convenience of a single dose, enhancing complete response rates and improving quality of life for individuals with cancer. Clinical research suggests its efficacy is especially noteworthy for patients undergoing highly emetogenic chemotherapy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Which Global Regions Offer the Highest Growth in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031

This Report Delivers Insight On:

1. How big is the chemotherapy-induced nausea and vomiting (cinv) market, and how is it changing globally?

2. Who are the major companies in the chemotherapy-induced nausea and vomiting (cinv) market, and how are they performing?

3. What are the key opportunities and risks in the chemotherapy-induced nausea and vomiting (cinv) market right now?

4. Which products or customer segments are growing the most in the chemotherapy-induced nausea and vomiting (cinv) market?

5. What factors are helping or slowing down the growth of the chemotherapy-induced nausea and vomiting (cinv) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the chemotherapy-induced nausea and vomiting (cinv) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size from 2025 to 2034?

The market size for chemotherapy-induced nausea and vomiting (CINV) has seen robust growth in recent times. This market is projected to expand from $2.92 billion in 2024 to $3.15 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.9%. Factors contributing to the growth during the historic period include an increase in chemotherapy usage, enhanced antiemetic agents, emerging clinical guidelines, and patient advocacy.

The market for Chemotherapy-Induced Nausea and Vomiting (CINV) is predicted to experience robust expansion in the forthcoming years, reaching a valuation of $4.2 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 7.5%. This development anticipated over the forecast period can be credited to personalized therapeutic approaches, advancements in antiemetic drugs, telehealth and remote supervision, and health equality efforts. Key trends expected during the forecast timeline comprise combined antiemetic treatments, ancillary care amenities, digital health mechanisms, and convalescent care.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

The surge in cancer cases is projected to stimulate the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the future. Cancer arises from a disordered multiplication and proliferation of body cells that infiltrate and damage other organs. With the growing incidences of cancer, there is an incremental urge to devise efficient and specific anti-emetic treatments to mitigate CINV, an undesirable consequence of chemotherapy. This increased interest in CINV control has guided progress in comprehending its fundamental causes and formulating new treatments. For example, the American Cancer Society (ACS), a US-based voluntary health body dedicated to abolishing cancer, anticipated in January 2023 that the country would witness around 1.9 million fresh cancer cases (about 5,370 instances daily) and approximately 609,820 cancer-related fatalities (roughly 1,670 deaths daily) in the year 2023. Thus, with the escalating prevalence of cancer, the chemotherapy-induced nausea and vomiting (CINV) market is expected to flourish. A noteworthy surge in the chemotherapy-induced nausea and vomiting (CINV) market is anticipated, driven by the escalating favorable regulatory initiatives. These initiatives define actions undertaken by regulating authorities to institute, execute, or impose regulations. These regulatory efforts can help enhance the CINV prevention and control and facilitate the formulation and application of guidelines for CINV. In one instance, the Food and Drug Administration, a US federal agency entrusted with public health protection, mentioned in October 2024 that in 2023, CDER (Center for Drug Evaluation and Research, a part of the U.S. Food and Drug Administration) sanctioned 55 unique drugs for chemotherapy-induced nausea and vomiting (CINV). Hence, the growing favorable regulatory initiatives are propelling the chemotherapy-induced nausea and vomiting (CINV) market’s expansion.

Which Segments in the Chemotherapy-Induced Nausea and Vomiting (CINV) Offer the Most Growth?

The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented –

1) By Form: Injectables, Oral, Transdermal Patches

2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class

3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

Subsegments:

1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

2) By Oral: Tablets, Capsules, Liquid Formulations

3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

What Are the Fastest-Growing Geographies in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Current Market Growth and Trends in the Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?

Leading businesses in the chemotherapy-induced nausea and vomiting (CINV) market are focusing on the development of unique products like a fixed intravenous antiemetic to establish a competitive edge. This refers to a set dosing of medicine delivered via IV to alleviate or prevent queasiness and vomiting, typically post-surgery or during chemotherapy. For instance, in January 2023, Glenmark Pharmaceuticals Limited, a pharmaceuticals, generics and over-the-counter (OTC) products production company based in India, launched AKYNZEO I.V. in India; this marked the country’s first-ever fixed intravenous antiemetic combo created to tackle chemotherapy-induced nausea and vomiting (CINV). The product merges netupitant and palonosetron and targets both the early and delayed stages of nausea and vomiting. The product offers convenience of a single dose, increases the complete response rates and enhances the life quality of cancer patients. Evidence from clinical studies suggest that patients undergoing highly emetogenic chemotherapy find it particularly advantageous.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

What Are the Key Elements That Define the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Chemotherapy-induced nausea and vomiting (CINV) is a condition that causes nausea and vomiting sensation, which can develop due to chemotherapy treatment. It is a prevalent side-effect affecting many cancer patients, affecting their quality of life and treatment results. CINV can be managed and treated through medications and lifestyle changes.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theChemotherapy-Induced Nausea and Vomiting (CINV) Market?

The rise in cancer cases is anticipated to spur the development of the chemotherapy-induced nausea and vomiting (CINV) market. Uncontrolled cell growth and spreading across the body is the essence of cancer. As cancer incidence increases, there is a heightened drive towards the creation of more proficient, specialized anti-emetic treatments to mitigate CINV, an uncomfortable chemotherapy complication. This emphasis on managing CINV has resulted in strides in comprehending its basic processes and initiating new therapies. For example, the American Cancer Society (ACS), a US-based volunteer health organization committed to eradicating cancer, predicted approximately 5,370 new cancer cases per day (totalling to 1.9 million annually) and around 1,670 cancer-related deaths daily (totalling to 609,820 annually) in the United States in 2023. Hence, the rising cancer prevalence is a primary driver for the CINV market’s growth.

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Driver: Positive Regulatory Initiatives Propel the Growth of the CINV Market

 

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

#What is the Projected CAGR for the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size from 2025 to 2034?

The market for Chemotherapy-Induced Nausea and Vomiting (CINV) has seen robust growth in recent times. It is projected to expand from a market size of $2.92 billion in 2024 to reach $3.15 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.9%. Factors such as the increased use of chemotherapy, enhancements in antiemetic agents, the establishment of clinical guidelines, and patient advocacy have all contributed to the upward trajectory during the past period.

Expectations predict robust expansion in the chemotherapy-induced nausea and vomiting (CINV) market size in the up-coming years. Projected to ascend to a value of $4.2 billion in 2029, its compound annual growth rate (CAGR) is estimated at 7.5%. Factors leading to advancement during the forecast period include personalized treatments, improvements in antiemetic medications, telehealth, remote monitoring programs, and health equity drives. The period’s principal trends constitute combined antiemetic treatment methods, supplemental care services, digital healthcare devices, and survivorship care.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031

What Are the Current Market Growth and Trends in theChemotherapy-Induced Nausea and Vomiting (CINV) Market That Industry Players Should Watch?

Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are working on new product innovations, such as fixed intravenous antiemetic, to gain a competitive advantage. A fixed intravenous antiemetic refers to a predetermined dose of medication administered through an IV to prevent or treat nausea and vomiting, commonly used in chemotherapy or post-surgery settings. For instance, in January 2023, Glenmark Pharmaceuticals Limited, an India-based manufacturer of pharmaceuticals, generics, and over-the-counter (OTC) products, introduced AKYNZEO I.V. in India, the first fixed intravenous antiemetic combination designed to prevent chemotherapy-induced nausea and vomiting (CINV). The product combines netupitant and palonosetron, targeting both acute and delayed phases of nausea and vomiting. It offers single-dose convenience, improved complete response rates, and enhanced quality of life for cancer patients. Clinical studies show it is particularly beneficial for highly emetogenic chemotherapy patients.

What Are the Major Market Players Making an Impact on theChemotherapy-Induced Nausea and Vomiting (CINV) Market Growth?

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

How Are the Key Segments of the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Driving Opportunities and Innovations?

The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented –

1) By Form: Injectables, Oral, Transdermal Patches

2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class

3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

Subsegments:

1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

2) By Oral: Tablets, Capsules, Liquid Formulations

3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theChemotherapy-Induced Nausea and Vomiting (CINV) Market?# Market Expansion?

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2025, By The Business Research Company:

High Performance Liquid Chromatography Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/high-performance-liquid-chromatography-global-market-report

High Performance Liquid Chromatography Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/high-performance-liquid-chromatography-global-market-report

Gas Chromatography Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gas-chromatography-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Long-Term Projected Growth Rate for the Chemotherapy-Induced Nausea and Vomiting (CINV) Market, and What Are the Key Drivers?

The market for chemotherapy-induced nausea and vomiting (CINV) has seen robust growth in the past few years. With a projected compound annual growth rate (CAGR) of 7.9%, it is expected to rise from $2.92 billion in 2024 to $3.15 billion in 2025. The market’s growth during the historical period can be attributed to factors such as an increase in the use of chemotherapy, the development of better antiemetic drugs, clinical guidelines, and patient advocacy.

The market for chemotherapy-induced nausea and vomiting (CINV) is projected to experience significant expansion in the coming years, reaching a value of $4.2 billion by 2029 with a compound annual growth rate (CAGR) of 7.5%. The expected increase during the prediction period can be linked to personalized medicine, advances in antiemetic agents, the adoption of telehealth and remote monitoring, as well as health equity initiatives. Combination antiemetic treatments, supportive care services, digital health tools, and survivorship care form the key trends anticipated in the future.

What Drivers Are Shaping the Growth of the chemotherapy-induced nausea and vomiting (cinv) Market?

Rising cancer rates are projected to fuel the expansion of the chemotherapy-induced nausea and vomiting (CINV) market. The uncontrolled and widespread growth of some body cells characterizes cancer. The continuous rise in cancer cases necessitates the creation of more potent and adapted anti-emetic treatments to mitigate CINV, a harrowing chemotherapy side effect. This increased focus on CINV management has led to progress in comprehending its underlying causes and producing new treatments. For example, predictions made by the American Cancer Society (ACS), a US-based voluntary health group dedicated to eliminating cancer, anticipate approximately 1.9 million new cancer case (about 5370 cases each day) and 609,820 cancer deaths (around 1,670 deaths each day) in the US in January 2023. As a result, the growing prevalence of cancer is expected to stimulate the chemotherapy-induced nausea and vomiting (CINV) market. Moreover, increasing favorable regulatory measures are projected to drive the chemotherapy-induced nausea and vomiting (CINV) market’s progress. Regulatory initiatives, taken by regulatory authorities to establish, implement, or enforce regulations, can be leveraged to foster the prevention and control of chemotherapy-induced nausea and vomiting (CINV) and also to establish and enforce guidelines for CINV prevention and control. For instance, in 2023, as per the Food and Drug Administration, a federal agency dedicated to protecting public health in the US, the Center for Drug Evaluation and Research (CDER) approved 55 new drugs for chemotherapy-induced nausea and vomiting (CINV) in October 2024. Therefore, these increasingly favorable regulatory measures are serving to further the growth of the chemotherapy-induced nausea and vomiting (CINV) market.

Get Your Free Sample of the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

Which Companies Are Leading the Charge in Expanding the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are:

• Pfizer Inc._x000D_

• Roche Holding AG_x000D_

• Merck & Co. Inc._x000D_

• AbbVie Inc._x000D_

• Novartis AG_x000D_

What New Trends Are Reshaping the Chemotherapy-Induced Nausea and Vomiting (CINV) Market and Its Opportunities?

Leading businesses in the chemotherapy-induced nausea and vomiting (CINV) marketplace are focusing on fresh product advancements, like fixed intravenous antiemetic, to establish a competitive edge. A fixed intravenous antiemetic is a pre-set quantity of medication given via an IV to prevent or manage nausea and vomiting, which is typically utilized in chemotherapy or following surgical procedures. To illustrate, Glenmark Pharmaceuticals Limited, a pharmaceutical, generics, and over-the-counter (OTC) products manufacturer from India, launched AKYNZEO I.V. in India in January 2023. This was the inaugural fixed intravenous antiemetic combination created to curb chemotherapy-induced nausea and vomiting (CINV). This product fuses netupitant and palonosetron, aiming to alleviate both the immediate and subsequent stages of nausea and vomiting. It provides the convenience of a single dosage, enhances complete response rates, and improves the quality of life for cancer patients. Clinical trials indicate it is particularly effective for patients undergoing highly emetogenic chemotherapy.

Get Instant Access to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

What Major Market Segments Define the Scope and Growth of the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented –

1) By Form: Injectables, Oral, Transdermal Patches

2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class

3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

Subsegments:

1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

2) By Oral: Tablets, Capsules, Liquid Formulations

3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

What Are the Top Regions Fueling Growth in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Defining Features of the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Chemotherapy-induced nausea and vomiting (CINV) is a condition that causes nausea and vomiting sensation, which can develop due to chemotherapy treatment. It is a prevalent side-effect affecting many cancer patients, affecting their quality of life and treatment results. CINV can be managed and treated through medications and lifestyle changes.

Browse Through More Similar Reports By The Business Research Company:

High Performance Liquid Chromatography Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/high-performance-liquid-chromatography-global-market-report

High Performance Liquid Chromatography Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/high-performance-liquid-chromatography-global-market-report

Gas Chromatography Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gas-chromatography-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: